Summary of findings table ‐ Daratumumab plus standard therapy vs usual care
Mortality within the longest · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower on‐study mortality (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
- Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple… 2024 · Cochrane Headline outcomes onlyRisk Ratio 0.72 [0.62, 0.83]3 studies · 1644 participantsModerate